Executing rare disease trials successfully in China: Operational considerations for global sponsors
As China's role in global rare disease research continues to expand, many sponsors are moving beyond the question of whether to include China in clinical development plans and focusing instead on how to do so effectively.
The opportunity is clear. China offers a large rare disease patient population, an evolving regulatory framework, growing clinical trial infrastructure and increasing alignment with global development strategies. However, as with any market, successful execution requires a thorough understanding of local requirements, logistics and operational considerations.
For sponsors planning rare disease programs, taking a proactive approach to regulatory planning, site selection and patient engagement can help maximize the value of conducting research in China.
Common misconceptions about conducting clinical trials in China
Despite the significant progress China has made in recent years, some misconceptions persist among sponsors outside the region. One common assumption is that China primarily supports local registration strategies. In reality, regulatory reforms have enabled earlier participation in global clinical development and increased involvement in multi-regional clinical trials.
Another misconception is that operational requirements are too complex to navigate efficiently. While China has unique regulatory processes and sample management requirements, these pathways are well-established and increasingly familiar to organizations conducting international studies.
As China's clinical research ecosystem has matured, sponsors have gained access to a more sophisticated and globally connected environment for rare disease development.
Understanding China's regulatory requirements for rare disease trials
Regulatory planning remains one of the most important components of study execution. Rare disease programs often require close collaboration with regulators throughout development, particularly when considering innovative study designs, limited patient populations or accelerated approval pathways.
China has placed greater emphasis on communication between sponsors and regulatory authorities, creating opportunities for earlier discussions around development plans, clinical endpoints and registration strategies. This can be particularly valuable in rare disease programs where traditional development models may not always be practical.
Building regulatory considerations into development planning early can help sponsors anticipate requirements, align timelines and support smoother study execution.
Navigating human genetic resource requirements
A key consideration for many global studies involving China is compliance with Human Genetic Resources Administration of China (HGRAC) requirements. Studies involving the collection, analysis or international transfer of certain genetic materials must comply with specific regulations and approval pathways. These requirements are intended to govern the use of human genetic resources while supporting scientific research and international collaboration.
Sponsors that address HGRAC considerations early in the planning process are often better positioned to avoid delays during study startup. Given the importance of genetics and biomarker research in many rare disease programs, understanding these requirements has become increasingly important.
Biospecimen planning and sample logistics
Rare disease studies frequently involve extensive laboratory testing, biomarker analyses and genetic assessments. As a result, biospecimen management should be considered from the earliest stages of study design.
China has established regulatory pathways that allow many commonly collected biosamples, including plasma, serum, urine and tissue slides, to be transferred internationally following appropriate approvals. However, certain materials remain subject to additional restrictions and handling requirements.
Developing a clear biospecimen strategy early can help support laboratory operations, reduce administrative burden and prevent disruptions later in the study. For rare disease programs that rely heavily on genetic analysis, sample management often becomes a critical component of overall trial planning.
Clinical trial site selection strategies for rare disease trials in China
Site selection can have a significant impact on recruitment, protocol adherence and overall study performance. China's clinical trial infrastructure continues to expand, with many leading hospitals developing substantial experience across complex therapeutic areas. Specialized centers that focus on rare diseases often maintain access to concentrated patient populations and established referral networks.
Sponsors should evaluate potential sites based not only on patient availability but also on operational capabilities, experience with rare disease protocols and access to multidisciplinary care teams. Strong site relationships can support consistent study execution and contribute to positive experiences for both investigators and patients.
Quality and inspection readiness
Quality remains a central focus for sponsors conducting research anywhere in the world. China's clinical research environment has become increasingly aligned with international standards. Regulatory authorities continue to strengthen oversight while organizations across the industry have enhanced quality management systems and inspection preparedness.
For global studies, maintaining consistent quality standards across all regions is essential. Sponsors should consider inspection readiness from study startup through database lock, with particular attention to documentation practices, protocol compliance and data integrity. A well-structured quality strategy not only supports regulatory expectations but also contributes to more reliable study outcomes.
The importance of local knowledge
Even with increased global alignment, successful execution in China still benefits from local insight. Regulatory timelines, startup activities, site engagement strategies and patient recruitment approaches may differ from those used in other regions. Organizations that understand the local landscape are often better positioned to anticipate challenges and identify opportunities throughout the study lifecycle.
For rare disease programs, this can be particularly valuable given the complexity of patient identification, referral pathways and stakeholder engagement.
Supporting rare disease development in China
Fortrea has supported clinical research activities in China for more than two decades and has experience across a broad range of therapeutic areas and development phases. We have conducted hundreds of studies in China and have supported rare disease programs globally across dozens of countries. Fortrea's teams have extensive experience supporting regulatory submissions, site activation, clinical operations and global development programs within the region. Learn more about how Fortrea can support your rare disease study.
As more sponsors incorporate China into global rare disease strategies, practical experience with regulatory processes, site networks and operational planning becomes increasingly important.
Key Success Factors for Rare Disease Trial Execution in China
China's rare disease ecosystem has evolved considerably over the past decade. Regulatory modernization, expanded clinical infrastructure, enhanced patient identification capabilities and growing international collaboration have created new opportunities for sponsors conducting global research.
Success in China requires thoughtful planning, strong operational execution and an understanding of local requirements. Organizations that take a strategic approach to regulatory engagement, site selection and patient recruitment will be better positioned to take advantage of the opportunities the country offers.
For rare disease sponsors looking to accelerate development and expand access to patients, China is becoming an increasingly important component of global clinical research strategies.